Article Information
History
- April 17, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Juan Manuel Carreño1,7,&,*,
- Gagandeep Singh1,7,*,
- Johnstone Tcheou1,7,
- Komal Srivastava1,7,
- Charles Gleason1,7,
- Hiromi Muramatsu2,
- Parnavi Desai1,7,
- Judith A. Aberg3,
- Rachel L. Miller4,
- PARIS study group1,7,
- Norbert Pardi2,
- Viviana Simon1,3,5,6,7,& and
- Florian Krammer1,6,7,&
- 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 2Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104, USA
- 3Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 4Division of Clinical Immunology, Department of Medicine, Icahn School of Medicine at Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 5The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 6Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 7Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ↵&To whom correspondance should be addressed: Florian Krammer (florian.krammer{at}mssm.edu), Viviana Simon (viviana.simon{at}mssm.edu) and Juan Manuel Carreño (jm.carreno{at}mssm.edu)
↵* Contributed equally
Posted April 17, 2022.
mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations
